Deals this week: Dova Pharmaceuticals Inc, Gamida Cell Ltd, Onxeo SA
US-based clinical-stage pharmaceutical company Dova Pharmaceuticals Inc is intending to raise between $60.93m and $69.06m through an initial public offering (IPO) of 4,062,500 shares of its common stock. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2017 Category: Pharmaceuticals Source Type: news
M & As this week: Shanghai ChemPartner Co, Cell Medica, BBI Group Holding
ShangPharma Corporation's contract research subsidiary Shanghai ChemPartner Co Ltd is set to merge with Quantum Hi-Tech (China) Biological Co Ltd. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2017 Category: Pharmaceuticals Source Type: news
Novartis reports positive top-line data from Phase III trial of cardiovascular drug
Novartis has reported positive top-line results from the Phase III CANTOS clinical trial of ACZ885 (canakinumab) and standard-of-care combination to address cardiovascular risk in patients who survived a heart attack. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2017 Category: Pharmaceuticals Source Type: news
Chi-Med commences Phase I/II trial of HMPL-453 for solid tumours
Hutchison China MediTech (Chi-Med) has commenced a Phase I/II clinical trial of HMPL-453 in China for the treatment of solid tumours in patients carrying fibroblast growth factor receptor (FGFR) genetic alteration. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2017 Category: Pharmaceuticals Source Type: news
CTD Holdings starts enrolment in Phase I/II trial of Trappsol Cyclo for NPC
US-based biotechnology firm CTD Holdings has started patient enrolment in the Phase I/II clinical trial of Trappsol Cyclo to treat patients suffering from Niemann-Pick disease type C (NPC) in Europe. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2017 Category: Pharmaceuticals Source Type: news
